Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial

Choudhary, MC; Chew, KW; Deo, R; Flynn, JP; Regan, J; Crain, CR; Moser, C; Hughes, MD; Ritz, J; Ribeiro, RM; Ke, R; Dragavon, JA; Javan, AC; Nirula, A; Klekotka, P; Greninger, AL; Fletcher, CV; Daar, ES; Wohl, DA; Eron, JJ; Currier, JS; Parikh, UM; Sieg, SF; Perelson, AS; Coombs, RW; Smith, DM; Li, JZ

Li, JZ (通讯作者)，Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Infect Dis, Boston, MA 02115 USA.;Smith, DM (通讯作者)，Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.

NATURE MICROBIOLOGY, 2022; 7 (11): 1906

Abstract

SARS-CoV-2 mutations that cause resistance to monoclonal antibody (mAb) therapy have been reported. However, it remains unclear whether in vivo emerge......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索